Published in Science on September 10, 2015
T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer. N Engl J Med (2016) 3.61
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science (2016) 3.38
Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy. Science (2017) 2.72
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma. Cell (2016) 2.65
Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance. Nat Genet (2016) 2.28
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer (2016) 2.19
The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol (2016) 2.09
Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy. Cell (2016) 2.00
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science (2016) 1.95
Combination cancer immunotherapies tailored to the tumour microenvironment. Nat Rev Clin Oncol (2015) 1.54
The Basis of Oncoimmunology. Cell (2016) 1.47
Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal. Ann Oncol (2017) 1.39
In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target. Nature (2017) 1.39
Cancer immunotherapy: the beginning of the end of cancer? BMC Med (2016) 1.32
Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol (2016) 1.26
Novel technologies and emerging biomarkers for personalized cancer immunotherapy. J Immunother Cancer (2016) 1.22
Clinical relevance of host immunity in breast cancer: from TILs to the clinic. Nat Rev Clin Oncol (2015) 1.22
Neoantigen landscape dynamics during human melanoma-T cell interactions. Nature (2016) 1.12
Translating RNA sequencing into clinical diagnostics: opportunities and challenges. Nat Rev Genet (2016) 1.12
Recurrent SERPINB3 and SERPINB4 mutations in patients who respond to anti-CTLA4 immunotherapy. Nat Genet (2016) 1.11
Driving CAR T-cells forward. Nat Rev Clin Oncol (2016) 1.09
Acquired resistance to immunotherapy and future challenges. Nat Rev Cancer (2016) 1.08
Classifying the evolutionary and ecological features of neoplasms. Nat Rev Cancer (2017) 1.07
Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. Cancer Discov (2016) 1.06
Prospects for gene-engineered T cell immunotherapy for solid cancers. Nat Med (2016) 1.03
Immune suppressive mechanisms in the tumor microenvironment. Curr Opin Immunol (2015) 1.02
Personalized Oncology Meets Immunology: The Path toward Precision Immunotherapy. Cancer Discov (2016) 0.96
Roles of regulatory T cells in cancer immunity. Int Immunol (2016) 0.95
Rational bases for the use of the Immunoscore in routine clinical settings as a prognostic and predictive biomarker in cancer patients. Int Immunol (2016) 0.94
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell (2017) 0.94
Genomic alterations and molecular subtypes of gastric cancers in Asians. Chin J Cancer (2016) 0.93
The efficacy of anti-PD-1 agents in acral and mucosal melanoma. Cancer (2016) 0.92
Cancer immunotherapy targeting neoantigens. Semin Immunol (2015) 0.92
The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine. Genome Med (2016) 0.92
The role of neoantigens in response to immune checkpoint blockade. Int Immunol (2016) 0.90
Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade. Cancer Immunol Res (2016) 0.88
CANCER. The odds of immunotherapy success. Science (2015) 0.86
Targeting neoantigens for cancer immunotherapy. Int Immunol (2016) 0.84
Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors. Proc Natl Acad Sci U S A (2016) 0.84
Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry. Nat Commun (2016) 0.83
Melanoma in 2015: Immune-checkpoint blockade - durable cancer control. Nat Rev Clin Oncol (2016) 0.83
Advances in immunotherapy for melanoma. BMC Med (2016) 0.83
Gene-expression profiling to predict responsiveness to immunotherapy. Cancer Gene Ther (2016) 0.83
Meningioma Genomics: Diagnostic, Prognostic, and Therapeutic Applications. Front Surg (2016) 0.82
Profile of nivolumab in the treatment of metastatic squamous non-small-cell lung cancer. Onco Targets Ther (2016) 0.82
Mutations as munitions: Neoantigen vaccines get a closer look as cancer treatment. Nat Med (2016) 0.82
Kinase Regulation of Human MHC Class I Molecule Expression on Cancer Cells. Cancer Immunol Res (2016) 0.82
Burden of Nonsynonymous Mutations among TCGA Cancers and Candidate Immune Checkpoint Inhibitor Responses. Cancer Res (2016) 0.81
Dendritic cell-based immunotherapy. Cell Res (2016) 0.81
Genomic Approaches to Understanding Response and Resistance to Immunotherapy. Clin Cancer Res (2016) 0.81
Tumor Microenvironment and Immunotherapy: The Whole Picture Is Better Than a Glimpse. Immunity (2015) 0.81
The role of immune checkpoint inhibition in the treatment of ovarian cancer. Gynecol Oncol Res Pract (2016) 0.81
Immunotherapy and Oncogenic Pathways: The PTEN Connection. Cancer Discov (2016) 0.80
PD-L1 expression in non-small cell lung cancer: Correlations with genetic alterations. Oncoimmunology (2016) 0.80
Dendritic Cells and Cancer Immunity. Trends Immunol (2016) 0.80
Mechanisms of immune evasion and current status of checkpoint inhibitors in non-small cell lung cancer. Cancer Med (2016) 0.80
Claudin-low bladder tumors are immune infiltrated and actively immune suppressed. JCI Insight (2016) 0.80
Dynamic versus static biomarkers in cancer immune checkpoint blockade: unravelling complexity. Nat Rev Drug Discov (2017) 0.80
Low Mutation Burden in Ovarian Cancer May Limit the Utility of Neoantigen-Targeted Vaccines. PLoS One (2016) 0.79
Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation. J Immunother Cancer (2016) 0.79
Integrated genomic analyses reveal frequent TERT aberrations in acral melanoma. Genome Res (2017) 0.79
Durable Complete Response from Metastatic Melanoma after Transfer of Autologous T Cells Recognizing 10 Mutated Tumor Antigens. Cancer Immunol Res (2016) 0.79
High-content molecular profiling of T-cell therapy in oncology. Mol Ther Oncolytics (2016) 0.79
Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity (2017) 0.79
Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set. BMC Med (2016) 0.78
Drug discovery in advanced prostate cancer: translating biology into therapy. Nat Rev Drug Discov (2016) 0.78
Genomic landscape of high-grade meningiomas. NPJ Genom Med (2017) 0.78
MAGE expression in head and neck squamous cell carcinoma primary tumors, lymph node metastases and respective recurrences-implications for immunotherapy. Oncotarget (2017) 0.78
Combination immunotherapy: a road map. J Immunother Cancer (2017) 0.77
Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis. Oncoimmunology (2017) 0.77
Targeted Therapies for Melanoma Brain Metastases. Curr Treat Options Neurol (2017) 0.77
Tissue-specific tumorigenesis: context matters. Nat Rev Cancer (2017) 0.77
Unmasking targets of antitumor immunity via high-throughput antigen profiling. Curr Opin Biotechnol (2016) 0.77
When Genome Maintenance Goes Badly Awry. Mol Cell (2016) 0.77
Biomarkers for immune therapy in colorectal cancer: mismatch-repair deficiency and others. J Gastrointest Oncol (2016) 0.77
Correlation of Apobec Mrna Expression with overall Survival and pd-l1 Expression in Urothelial Carcinoma. Sci Rep (2016) 0.77
Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer. J Clin Invest (2016) 0.77
SHP-1: the next checkpoint target for cancer immunotherapy? Biochem Soc Trans (2016) 0.77
Monitoring immune responses in the tumor microenvironment. Curr Opin Immunol (2016) 0.77
Combination Therapies for Melanoma: A New Standard of Care? Am J Clin Dermatol (2016) 0.77
A second chance for telomerase reverse transcriptase in anticancer immunotherapy. Nat Rev Clin Oncol (2016) 0.77
Implementing liquid biopsies into clinical decision making for cancer immunotherapy. Oncotarget (2017) 0.77
Applied Cancer Immunogenomics: Leveraging Neoantigen Discovery in Glioblastoma. Cancer J (2017) 0.76
Comparison of the Lonidamine Potentiated Effect of Nitrogen Mustard Alkylating Agents on the Systemic Treatment of DB-1 Human Melanoma Xenografts in Mice. PLoS One (2016) 0.76
Prioritization schema for immunotherapy clinical trials in glioblastoma. Oncoimmunology (2016) 0.76
PD-L1 (CD274) copy number gain, expression, and immune cell infiltration as candidate predictors for response to immune checkpoint inhibitors in soft-tissue sarcoma. Oncoimmunology (2017) 0.76
DNA damage, tumor mutational load and their impact on immune responses against cancer. Ann Transl Med (2016) 0.76
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression. Genome Med (2015) 0.76
Molecular characterisation of cutaneous melanoma: creating a framework for targeted and immune therapies. Br J Cancer (2016) 0.76
Precision medicine for advanced prostate cancer. Curr Opin Urol (2016) 0.76
Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines. Pharmacol Ther (2017) 0.76
The immune contexture in cancer prognosis and treatment. Nat Rev Clin Oncol (2017) 0.75
Immunotherapy in human colorectal cancer: Challenges and prospective. World J Gastroenterol (2016) 0.75
The genetics of uveal melanoma: current insights. Appl Clin Genet (2016) 0.75
Immunotherapy in the Precision Medicine Era: Melanoma and Beyond. PLoS Med (2016) 0.75
Neoantigen-based cancer immunotherapy. Ann Transl Med (2016) 0.75
Immunotherapy in glioblastoma: emerging options in precision medicine. CNS Oncol (2016) 0.75
Definitive chemoradiation alters the immunologic landscape and immune checkpoints in head and neck cancer. Br J Cancer (2016) 0.75
The Relationship Between Dormant Cancer Cells and Their Microenvironment. Adv Cancer Res (2016) 0.75
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer (2009) 77.71
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Integrative genomics viewer. Nat Biotechnol (2011) 42.83
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011) 26.90
Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res (2009) 24.11
Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med (2014) 16.83
Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol (2013) 16.13
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med (2015) 14.71
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med (2015) 13.08
A landscape of driver mutations in melanoma. Cell (2012) 12.61
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science (2015) 11.89
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med (2015) 7.51
The future of immune checkpoint therapy. Science (2015) 5.59
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. J Clin Oncol (2015) 5.49
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature (2014) 5.34
Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J Clin Oncol (2013) 5.23
Neoantigens in cancer immunotherapy. Science (2015) 5.16
Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science (2015) 4.29
Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell (2015) 4.16
Genomic Classification of Cutaneous Melanoma. Cell (2015) 3.91
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Nature (2015) 3.86
Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature (2014) 3.42
Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. Nat Med (2014) 3.18
ContEst: estimating cross-contamination of human samples in next-generation sequencing data. Bioinformatics (2011) 2.90
Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature (2015) 2.76
High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma. Nat Med (2014) 2.40
Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival. Genome Res (2014) 2.03
Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen. Science (1999) 2.01
Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. J Clin Oncol (2015) 1.66
Impact of NRAS mutations for patients with advanced melanoma treated with immune therapies. Cancer Immunol Res (2015) 1.20
Biomarkers in cancer immunotherapy. Cancer Cell (2015) 1.16
High frequency of melanoma-associated antigen or HLA class I loss does not correlate with survival in primary melanoma. J Immunother (2003) 0.94